← Back to home

Amgen Drug Added to Immunotherapy Cuts Death Risk 58% in Small Cell Lung Cancer Trial

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Adding Amgen's drug Imdelltra to AstraZeneca's immunotherapy Imfinzi lowered patients' risk of dying 58% compared…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

3 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home